# Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)

> **NCT06162728** · PHASE1,PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Jasper Therapeutics, Inc.** · enrollment: 88 (actual)

## Conditions studied

- Chronic Spontaneous Urticaria

## Interventions

- **DRUG:** Briquilimab
- **OTHER:** Placebo

## Key facts

- **NCT ID:** NCT06162728
- **Lead sponsor:** Jasper Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1,PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2023-11-29
- **Primary completion:** 2026-10-31
- **Final completion:** 2026-10-31
- **Target enrollment:** 88 (ACTUAL)
- **Last updated:** 2026-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06162728

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06162728, "Dose Escalation Trial Of Safety, Pharmacokinetic/Pharmacodynamic And Preliminary Clinical Activity of Briquilimab In Adult Patients With Chronic Spontaneous Urticaria (CSU)". Retrieved via MORVS 2026-10-10 from https://api.morvs.ai/clinical/NCT06162728. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*